Hologic buys Interlace Medical for $125M

Hologic has agreed to pay $125 million to acquire privately held Interlace. The company makes the MyoSure hysteroscopic tissue removal system that helps easily remove fibroids and polyps. Hologic, a maker of diagnostics, imaging systems and surgical products dedicated for women's healthcare, will integrate the purchase into its GYN Surgical Products division.

"This product is a natural extension of our industry-leading OB/GYN product portfolio[,] which now provides women with minimally-invasive treatment options--from their child bearing years to menopause," said Steve Williamson, senior vice president and general manager, GYN Surgical Products. "The strong clinical performance and ease of use of the MyoSure device make it a natural fit with our NovaSure endometrial ablation and Adiana permanent contraception product lines."

- check out Hologic's release

Suggested Articles

Takeda tapped Roche’s Foundation Medicine to develop tissue- and blood-based companion diagnostic tests for its portfolio of lung cancer therapies.

Cellex has announced plans to develop a rapid coronavirus test that people can fully perform at home, from sample collection to result, using an app.

More than 20 states either don’t release or have incomplete data on the rapid antigen tests now considered key to containing the coronavirus.